Femasys Inc. (FEMY) | Investment Case

1. Company Snapshot

1.a. Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States.The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally.

The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists.In addition, it provides non-surgical product technologies.Femasys Inc.

was incorporated in 2004 and is based in Suwanee, Georgia.

Show Full description

1.b. Last Insights on FEMY

Femasys Inc.'s recent performance was driven by several positive developments. The company secured FDA approval to advance the final FemBloc trial phase, enabling progression toward U.S. FDA approval for its non-surgical permanent birth control. A $12 million senior secured convertible notes financing, with potential to reach $58 million, reflects strong investor confidence. Additionally, Femasys expanded its FemSperm product line with a new Insemination Prep Kit, broadening gynecology-based access to FemaSeed. Regulatory approvals in New Zealand and prior CE Mark and UK approvals also contributed to the company's growth.

1.c. Company Highlights

Last Price	0.88
Change Percentage	-2.17%
Open	0.91
Previous Close	0.9
Market Cap ( Millions)	26
Volume	1165084
Year High	1.8
Year Low	0.31
M A 50	0.72
M A 200	0.92

FCF Yield	-77.40%
Dividend Yield	0.00%
ROE	-764.17%
Debt / Equity	178.89%
Net Debt / EBIDTA	-47.59%
Price To Book	7.93
Price Earnings Ratio	-1.82
Price To FCF	-1.29
Price To sales	12.58
EV / EBITDA	-1.99

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov -25

Source: businesswire.com

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov -03

Source: globenewswire.com

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct -16

Source: globenewswire.com

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep -11

Source: globenewswire.com

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep -08

Source: globenewswire.com

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug -26

Source: globenewswire.com

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Aug -08

Source: zacks.com

Femasys Revenue Jumps 85 Percent in Q2

Aug -08

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

FemVue

Expected Growth: 8.5%

FemVue's 8.5% growth driven by increasing adoption in outpatient settings, rising demand for minimally invasive diagnostic tools, and growing awareness of cervical cancer screening. Expanding distribution channels, strategic partnerships, and investments in product development also contribute to growth.

7. Detailed Products

FlexiCath

A proprietary, sterile, and single-use urinary catheter system designed for intermittent self-catheterization.

MyoSure

A minimally invasive, hysteroscopic tissue removal system for the treatment of intrauterine pathology.

FemBloc

A non-surgical, permanent birth control system for women, using a minimally invasive procedure to occlude the fallopian tubes.

8. Femasys Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Femasys Inc. is moderate due to the availability of alternative products in the market.

Bargaining Power Of Customers

The bargaining power of customers is high due to the presence of a large number of competitors in the market, giving customers more options to choose from.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the company's strong relationships with its suppliers and the availability of alternative suppliers in the market.

Threat Of New Entrants

The threat of new entrants is moderate due to the moderate barriers to entry in the industry, including regulatory hurdles and capital requirements.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established competitors in the market, leading to a highly competitive environment.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	20.27%
Debt Cost	3.95%
Equity Weight	79.73%
Equity Cost	-9.87%
WACC	-7.07%
Leverage	25.42%

11. Quality Control: Femasys Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

InfuSystem Holdings

A-Score: 4.6/10

Value: 4.6

Growth: 5.7

Quality: 5.7

Yield: 0.0

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

Atrion

A-Score: 3.5/10

Value: 3.5

Growth: 3.0

Quality: 6.2

Yield: 1.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

NEXGEL

A-Score: 3.3/10

Value: 7.4

Growth: 4.9

Quality: 4.2

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

STAAR Surgical

A-Score: 3.2/10

Value: 8.0

Growth: 4.1

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

Femasys

A-Score: 2.7/10

Value: 6.0

Growth: 2.8

Quality: 3.1

Yield: 0.0

Momentum: 4.0

Volatility: 0.3

1-Year Total Return ->

Harvard Bioscience

A-Score: 2.2/10

Value: 9.2

Growth: 1.1

Quality: 2.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

4.56%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

-7.07%

Femasys Inc. - US31447E1055

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on FEMY

1.c. Company Highlights

Lower Quality

Medium Volatility

Average Growth

Earnings Beats

Average Quality

More Volatile

Earnings Miss

Average Yield

Stable Momentum

Revenues Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

FemVue

Expected Growth: 8.5%

7. Detailed Products

FlexiCath

MyoSure

FemBloc

8. Femasys Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Femasys Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.88$

Current Price

0.88$

Potential

0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA